Mr. Walbert has been a member of our board of directors since March 2014 and has served as our chair since June 2015. Mr. Walbert has been the president and chief executive officer of Horizon Pharma since June 2008 and has been the chairman of the Horizon board since 2010. Previously, he served as president, chief executive officer, and director of IDM Pharma, Inc., a public biopharmaceutical company which was acquired by Takeda America Holdings, Inc., or Takeda, in June 2009. Prior to IDM, Mr. Walbert served as executive vice president, commercial operations, at NeoPharm, Inc., a public biopharmaceutical company. From 2001 to 2005, Mr. Walbert served as divisional vice president and general manager, immunology, where he led the global development and launch of the multi-indication biologic HUMIRA, which had almost $20 billion in 2018 sales and divisional vice president, global cardiovascular strategy, at Abbott, now AbbVie. From 1998 to 2001, Mr. Walbert served as director, CELEBREX North America, and arthritis team leader, Asia Pacific, Latin America, and Canada at G.D. Searle & Company. From 1991 to 1998, Mr. Walbert also held sales and marketing roles with increasing responsibility at G.D. Searle, Merck & Co., Inc., and Wyeth. Mr. Walbert received his B.A. in business from Muhlenberg College. In addition to the Egalet board of directors, Mr. Walbert serves on the Biotechnology Innovation Organization (BIO), Illinois Biotechnology Innovation Organization (iBIO), World Business Chicago and Greater Chicago Arthritis Foundation boards. Mr. Walbert has prior public board experience on the boards of XOMA (NASDAQ, XOMA), Sucampo (NASDAQ, SCMP, acquired by Mallinckrodt) and Raptor (NASDAQ, RPTP, acquired by Horizon Pharma).
Mr. Luke Düster has been a member of the Egalet board of directors since January 31, 2019. He is a partner at CRG, a healthcare investment management firm, and leads CRG’s investment process from sourcing and due diligence through realization. Prior to CRG, Mr. Düster was an investment banker at Harris Williams & Co., where he advised private equity and corporate clients across a broad range of mergers and acquisitions. Mr. Düster also worked at the Wallach Company, a regional investment banking boutique, and the Nord Companies, a healthcare advisory firm. Mr. Düster received a bachelor’s degree from the University of Colorado at Boulder in 1997, where he graduated summa cum laude. Mr. Düster received an MBA with honors from the Wharton School at the University of Pennsylvania in 2004.
Mr. Todd Holmes joined our board of directors on January 31, 2019. Since joining in 2018, he has been a principal at CRG where he leads investment sourcing, diligence and execution in various sectors including specialty pharma, medical technology and healthcare services. Mr. Holmes has 15 years of investing, company building and transaction experience across private and public sectors. Prior to joining CRG, Mr. Holmes was an investor and founding member of Gurnet Point Capital where he led investments and acquisitions across multiple stages and sectors within healthcare.
Previously, Mr. Holmes was a member of Third Rock Ventures where he held investment and operational roles and was part of the founding team at Ember Therapeutics. Earlier in his career, he was an investor at BVF Partners, a biotechnology-focused hedge fund, and a member of the commercial lending practice at Silicon Valley Bank. Mr. Holmes received a bachelor’s degree in Economics from Colgate University and an MBA from the Wharton School at the University of Pennsylvania.
Mr. Joe McInnis has been a member of our board of directors since January 31, 2019. He has almost two decades of experience in finance. Since 2015, Mr. McInnis has been a principal at Murrin Construction, a provider of aggregates and dimension stone. Prior to joining Murrin, he was a managing director and investment analyst at Greywolf Capital which he joined in 2004. Before Greywolf, Mr. McInnis worked for three years as an investment analyst in the special situations investing group at Goldman Sachs & Co. In addition to being on our board, he is a director on the Aspire Oil & Gas and Washington Mutual board of directors. He received his bachelor’s at the University of British Columbia.
Mr. Pauls has been a member of our board of directors since January 31, 2019. He has more than 20 years of leadership experience in the pharmaceutical industry, with an emphasis on specialty pharma and orphan/rare diseases. Mr. Pauls brings extensive general management and commercial leadership experience, and has served as President, CEO and director of Strongbridge Biopharma plc since August of 2014. Strongbridge Biopharma, an Irish-domiciled company with U.S. headquarters in Trevose, Pennsylvania, is a NASDAQ-listed biopharma company focused on developing and commercializing therapies for rare diseases. Before joining Strongbridge, Mr. Pauls was the chief commercial officer at Insmed, a NASDAQ-listed biopharmaceutical company. Prior to that, he served as senior vice president, head of global commercial operations at Shire Pharmaceuticals and held senior positions at Bristol-Myers Squibb in brand management and payer marketing, and at Johnson & Johnson in various U.S. and global commercial roles. In addition to Egalet and Strongbridge, Mr. Pauls serves on the board of directors of Savara Pharmaceuticals The Pennington School in Pennington, New Jersey. He received a bachelor’s degree and an MBA from Central Michigan University and earned his JD from Michigan State University College of Law.
Mr. Radie is president, chief executive officer and a member of Egalet’s board of directors and has been since March 2012. Mr. Radie has had a successful career with more than three decades in the industry and has been responsible for the sale of five companies. In 2005 Mr. Radie led the sale of Vicuron Pharmaceuticals to Pfizer for $1.9 billion and most recently he was responsible for the sale of Topaz Pharmaceuticals Inc. to Sanofi Pasteur for an undisclosed amount. Mr. Radie served in senior management positions with a number of pharmaceutical and biotechnology companies, including Prestwick Pharmaceuticals, Inc., Morphotek, Inc., Vicuron Pharmaceuticals, Inc. and served as a director of Affinium Pharmaceuticals, Ltd. from July 2012 to March 2014, when a majority of Affinium’s assets were acquired by a third party. Mr. Radie began his career in the life sciences at Eli Lilly and Company where he worked for 18 years in sales and marketing positions with increasing levels of responsibility. Mr. Radie serves on the board of Paratek Pharmaceuticals, a biopharmaceutical company, Pennsylvania Bio, an industry group supporting Pennsylvania life sciences companies, Veloxis, a private commercial-stage company, and Horse Power for Life, a non-profit organization dedicated to improving the quality of life for individuals diagnosed with cancer. Mr. Radie received his B.S. in chemistry from Boston College.
Andrea Heslin Smiley
Ms. Smiley has served as a member of our board of directors since April 2017. She has approximately three decades of commercialization and general management experience in the biopharmaceutical industry in both public and private companies. Since 2011, Ms. Smiley has served as president and CEO at VMS BioMarketing, a leading provider of patient and healthcare provider support. Within her first year as CEO of VMS BioMarketing, she spun-off commoditized business units and focused the company solely on impacting patient adherence and outcomes. During her tenure as CEO, she has established VMS as the leading provider and growth leader of clinical nurse educator patient support solutions. Ms. Smiley provides strategic consulting to VMS’ biopharma clients on pre- and post-commercialization strategies across a broad range of therapeutic areas including immunology, oncology, endocrinology, neuroscience and rare diseases. Prior to joining VMS BioMarketing in 2008, Ms. Smiley spent 18 years at Eli Lilly and Company in various positions of increasing responsibility in finance, business development, corporate affairs, brand management and business unit leadership roles. Among other programs, she was the marketing leader for the launch of Humalog® Mix75/25™, she led sales and marketing for Humatrope®, she was responsible for the development and launch of Forteo® and she was the business unit leader of Lilly’s women’s health business. Earlier in her career, Ms. Smiley worked as a management consultant for Putnam Associates, where she led consulting teams and advised brands in the biotechnology, pharmaceutical and managed healthcare ﬁelds on product launches and access strategies. She is a regular speaker and panel member on patient adherence, patient services and women’s leadership topics at biopharma industry conferences. Ms. Smiley serves on the board of numerous nonprofit organizations including: Indiana Alzheimer’s Association, Summer Stock, Indiana Salvation Army and the Lung Force Women’s Cabinet. She received a gubernatorial appointment to the Indiana Commission for Women. In addition to Egalet, she is on the board of AppianRx, a privately held, technology-based specialty pharmacy and patient support solutions company. Ms. Smiley earned her BA in economics from DePauw University where she was an Honors Management Fellow.